优化新批准药物在急性髓系白血病中的应用
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia.
作者信息
Nix Nancy M, Price Allyson
机构信息
Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas.
出版信息
J Adv Pract Oncol. 2019 Nov-Dec;10(Suppl 4):9-18. doi: 10.6004/jadpro.2019.10.8.13. Epub 2019 Nov 1.
Abstract
Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease.
摘要
直到最近，自20世纪70年代以来，急性髓系白血病（AML）的治疗进展一直缓慢。然而，在过去几年中，随着对AML病理生理学的认识不断深入，美国食品药品监督管理局已批准了多种治疗方法。本文回顾了八种新型药物的作用机制、适应证和临床试验细节，以及目前围绕监测微小残留病的讨论。
相似文献
1
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia.
J Adv Pract Oncol. 2019 Nov-Dec;10(Suppl 4):9-18. doi: 10.6004/jadpro.2019.10.8.13. Epub 2019 Nov 1.
2
New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Pharmacotherapy. 2018 Nov;38(11):1143-1154. doi: 10.1002/phar.2180. Epub 2018 Oct 17.
3
New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
Clin Adv Hematol Oncol. 2019 Oct;17(10):569-575.
4
New and emerging therapies for acute myeloid leukaemia.
J Investig Med. 2018 Dec;66(8):1088-1095. doi: 10.1136/jim-2018-000807. Epub 2018 Aug 19.
5
Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
Leuk Res. 2020 Sep;96:106420. doi: 10.1016/j.leukres.2020.106420. Epub 2020 Jul 13.
6
Advances in treatment formulations for acute myeloid leukemia.
Drug Discov Today. 2018 Dec;23(12):1936-1949. doi: 10.1016/j.drudis.2018.05.040. Epub 2018 Jun 2.
7
New agents in acute myeloid leukemia (AML).
Blood Res. 2020 Jul 31;55(S1):S14-S18. doi: 10.5045/br.2020.S003.
8
Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):90-7. doi: 10.1016/j.beha.2015.10.005. Epub 2015 Oct 22.
9
Novel Agents for Acute Myeloid Leukemia.
Cancers (Basel). 2018 Nov 9;10(11):429. doi: 10.3390/cancers10110429.
10
A concise review of BCL-2 inhibition in acute myeloid leukemia.
Expert Rev Hematol. 2018 Feb;11(2):145-154. doi: 10.1080/17474086.2018.1420474. Epub 2018 Jan 3.
引用本文的文献
1
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study.
Adv Ther. 2024 Nov;41(11):4049-4064. doi: 10.1007/s12325-024-02947-1. Epub 2024 Sep 6.
2
Neuroprotective Effects of Chemical Constituents of Leaves of Wall.
Plants (Basel). 2024 Apr 13;13(8):1094. doi: 10.3390/plants13081094.
3
Antimicrobial, Cytotoxic, and Anti-Inflammatory Activities of Extracts.
Plants (Basel). 2023 Aug 31;12(17):3136. doi: 10.3390/plants12173136.
4
Molecular and epigenetic alterations in normal and malignant myelopoiesis in human leukemia 60 (HL60) promyelocytic cell line model.
Front Cell Dev Biol. 2023 Feb 2;11:1060537. doi: 10.3389/fcell.2023.1060537. eCollection 2023.
本文引用的文献
1
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches.
Ther Adv Hematol. 2019 Jul 10;10:2040620719860645. doi: 10.1177/2040620719860645. eCollection 2019.
2
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.
Core Evid. 2019 Apr 26;14:3-17. doi: 10.2147/CE.S172912. eCollection 2019.
3
How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:411-420. doi: 10.1200/EDBK_238687. Epub 2019 May 17.
4
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.
5
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.
6
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
7
Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
N Engl J Med. 2018 Sep 20;379(12):1186. doi: 10.1056/NEJMc1809507.
8
Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3.
9
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.
10
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Onco Targets Ther. 2018 Jun 12;11:3425-3434. doi: 10.2147/OTT.S141212. eCollection 2018.
Zotero 插件